[1] 谢潋滟, 孙景勇, 杨洋, 等. 2015—2021年CHINET临床分离铜绿假单胞菌耐药性变迁[J]. 中国感染与化疗杂志, 2024, 24(2): 198-205. [2] MOISE P A, GONZALEZ M, ALEKSEEVA I, et al. Collective assessment of antimicrobial susceptibility among the most common gram-negative respiratory pathogens driving therapy in the ICU[J]. JAC Antimicrob Resist, 2021, 3(1): dlaa129. [3] 中华医学会呼吸病学分会感染学组, 瞿介明, 施毅, 等. 中国铜绿假单胞菌下呼吸道感染诊治专家共识(2022年版)[J]. 中华结核和呼吸杂志, 2022, 45(8): 739-752. [4] REYES J, KOMAROW L, CHEN L, et al. Global epidemiology and clinical outcomes of carbapenem-resistant pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study[J]. Lancet Microbe, 2023, 4(3): e159-e170. [5] YAMIN D, USKOKOVIĆ V, WAKIL A M, et al. Current and future technologies for the detection of antibiotic-resistant bacteria[J]. Diagnostics:Basel, 2023, 13(20): 3246. [6] 中华医学会内分泌学分会,中国内分泌代谢病专科联盟. 糖皮质激素类药物临床应用指导原则(2023版)[J]. 中华内分泌代谢杂志,2023,39(4): 289-296. [7] 莫立乾, 郑萍. 免疫药物临床药学专家共识[J]. 今日药学, 2024, 34(11): 801-811. [8] GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050[J]. Lancet, 2024, 404(10459): 1199-1226. [9] 郭燕, 胡付品, 朱德妹, 等. 2023年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2024, 24(6): 627-637. [10] 王雪玉, 田芳英, 赵明. 全球铜绿假单胞菌医院感染暴发事件的流行特征与应对策略[J]. 中国感染控制杂志, 2022, 21(12): 1171-1178. [11] 俞蕙. 碳青霉烯类耐药铜绿假单胞菌耐药机制与治疗现状[J]. 临床儿科杂志, 2023, 41(8): 561-565. [12] LITWIN A, ROJEK S, GOZDZIK W, et al. Pseudomonas aeruginosa device associated-healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: Polish, 8.5-year, prospective, single-centre study[J]. BMC Infect Dis, 2021, 21(1): 180. [13] LIAO Q, FENG Z, LIN H, et al. Carbapenem-resistant gram-negative bacterial infection in intensive care unit patients: antibiotic resistance analysis and predictive model development[J]. Front Cell Infect Microbiol, 2023, 13: 1109418. |